PMID-20479765 – Tesofensine Energy Metabolism and Appetite
Sjodin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, Meier D, Astrup A. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010;34(11):1634-1643.
Quick Reference
| Property | Value |
|---|---|
| PMID | 20479765 |
| DOI | 10.1038/ijo.2010.87 |
| Year | 2010 |
| Journal | International Journal of Obesity |
| Study Type | RCT |
| Evidence Level | II |
| Sample | 32 overweight/moderately obese men |
| Peptide(s) Studied | Tesofensine |
Key Findings
- Tesofensine 0.5 mg significantly reduced 24-hour energy intake
- Appetite suppression was primarily driven by reduced hunger and increased satiety
- 24-hour energy expenditure was not significantly altered at the 0.5 mg dose
- Fat oxidation showed a trend toward increase but did not reach significance
- The weight loss mechanism is predominantly appetite suppression rather than thermogenesis
- Subjective appetite ratings confirmed reduced desire to eat
Study Design
Randomized, double-blind, placebo-controlled crossover study. 32 overweight/moderately obese men received tesofensine 0.5 mg or placebo for 14 days each, with a washout period. Energy intake and expenditure measured in a respiratory chamber. Visual analogue scales for appetite assessment.
Limitations
- Short duration (14 days per treatment period)
- Male-only population
- Small sample size (n=32)
- Crossover design may have carryover effects given tesofensine's long half-life (~200 hours)
Clinical Relevance
Clarifies that tesofensine's weight loss effects are primarily appetite-mediated rather than through increased energy expenditure. This has implications for patient selection — the drug is most suitable for individuals whose obesity is driven by hyperphagia rather than low metabolic rate. The long half-life supports once-daily dosing.
Related
#research #RCT #tesofensine #evidence-level-II